Literature DB >> 26329270

Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).

Els K Vanhoutte1, Catharina G Faber1, Sonja I van Nes2, Elisabeth A Cats3, W-Ludo Van der Pol3, Kenneth C Gorson4, Pieter A van Doorn2, David R Cornblath5, Leonard H van den Berg3, Ingemar S J Merkies1,6.   

Abstract

Clinical trials in multifocal motor neuropathy (MMN) have often used ordinal-based measures that may not accurately capture changes. We aimed to construct a disability interval outcome measure specifically for MMN using the Rasch model and to examine its clinimetric properties. A total of 146 preliminary activity and participation items were assessed twice (reliability studies) in 96 clinically stable MMN patients. These patients also assessed the ordinal-based overall disability sum score (construct, sample-dependent validity). The final Rasch-built overall disability scale for MMN (MMN-RODS(©) ) was serially applied in 26 patients with newly diagnosed or relapsing MMN, treated with intravenous immunoglobulin (IVIg) (1-year follow-up; responsiveness study). The magnitude of change for each patient was calculated using the minimum clinically important difference technique related to the individually obtained standard errors. A total of 121 items not fulfilling Rasch requirements were removed. The final 25-item MMN-RODS(©) fulfilled all Rasch model's expectations and showed acceptable reliability and validity including good discriminatory capacity. Most serially examined patients improved, but its magnitude was low, reflecting poor responsiveness. The constructed MMN-RODS(©) is a disease-specific, interval measure to detect activity limitations in patients with MMN and overcomes the shortcomings of ordinal scales. However, future clinimetric studies are needed to improve the MMN-RODS(©) 's responsiveness by longer observations and/or more rigorous treatment regimens.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  MMN; Rasch-built disability scale; multifocal motor neuropathy; outcome measure

Mesh:

Year:  2015        PMID: 26329270     DOI: 10.1111/jns.12141

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  3 in total

1.  Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.

Authors:  Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang
Journal:  Support Care Cancer       Date:  2018-11-20       Impact factor: 3.603

Review 2.  Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.

Authors:  Yusuf A Rajabally; H Stephan Goedee; Shahram Attarian; Hans-Peter Hartung
Journal:  Muscle Nerve       Date:  2020-04-24       Impact factor: 3.852

3.  IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®-The LIME Study.

Authors:  Jean-Marc Léger; Ousmane Alfa Cissé; Dario Cocito; Jean-Marie Grouin; Haider Katifi; Eduardo Nobile-Orazio; Rabye Ouaja; Jean Pouget; Yusuf A Rajabally; Teresa Sevilla; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2018-12-11       Impact factor: 3.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.